Almirall SA · BME:ALM
Almirall SA — IPO Roadshow (June 2007)
24 slides from Almirall SA's IPO roadshow presentation, June 2007
Slide 1: Almirall
i] . (% Almirall Solutions thinking of you
Slide 2: Company Presentation as of June 2007
Company Presentation as of June 2007 (before the acquisition of Hermal) 2
Slide 3: An R&D-driven international pharma company
An R&D-driven international pharma company… Headquartered in Barcelona, Spain • First Spanish international R&D based company – Founded in 1943, currently employs c. 2,900 people worldwide Headquarters – #1 Spanish company; #3 in the overall Spanish market – €758 MM sales and €144 MM EBITDA in 2006
Slide 4: …with significant R&D upside
…with significant R&D upside Historic Sales 2000–2006 (€ MM) Pipeline Overview CAGR = 8.3% Product Stage of Developmet 800 736 758 Aclidinium Bromide (AB) Phase III 676 700 > €2.0 Bn 632 215 241 AB + Formoterol Phase II 583 opportunity 161 169 AB + ICS Pre-Clinical 600 141 470 140 LAS 35201 Phase II
Slide 5: …having grown rapidly organically and through acquisitions
…having grown rapidly organically and through acquisitions Forest Aclidinium Bromide Partnership for US License of Axert to Worldwide Ebastine Axert transferred to Pharmacia recovery from RPR Pantopan and Acquisition of J&J Sativex Licenses inhalation platform • Axert launch in US 1997 Merger 1998-9
Slide 6: Global footprint through affiliates and local partnerships
Global footprint through affiliates and local partnerships 2006: Sales - €758 MM(1); Sales Force - 1,379(2) Belgium • Local Sales : €9 MM France • Sales Force: 25 heads • Local Sales : €66 MM • Sales Force: 223 heads Germany • Local Sales : €8 MM • Sales Force: 54 heads Spain • Local Sales : €571 MM
Slide 7: Key investment highlights
Key investment highlights • Attractive business model – Branded, patented and a well balanced product portfolio – Spanish leadership – Proven resilience to adverse market conditions – Growing international business through own affiliates and local partnerships • Strong R&D heritage – Designed to bal
Slide 8: The Almirall business model
The Almirall business model Income From Proprietary R&D Products (45%) Income From Other Companies Products Out-licensing Almirall Markets Quid-pro-quo (15%) In-licensing (40%) Almirall has strategic Almirall has consolidated Almirall has been a successful in-licensor of major partnerships globally
Slide 9: A branded, patented and well-balanced product portfolio
A branded, patented and well-balanced product portfolio… 44% of current sales come from proprietary R&D 2006 Sales by Therapeutic Area Top 10 Products in 2006 Other Product Name % of Group Own R&D In-Licensed Indication Cardiovascular Sales 7% Ebastine 13 Respiratory Osteomuscular 20% Prevencor 11 C
Slide 10: …has proven its resilience…
…has proven its resilience… Sales(2) (€ MM) 800 736 +3.0% 758 676 700 + 5.1% +3.6% 241 632 +7.0% 215 583 +8.4% 161 169 600 141 +24.0% 140 470 515 531 521 517 99 491 400 443 371 200 0 (1) 2000 2001 2002 2003 2004 2005 2006 Spanish Sales International and unassigned Sales Astudal Dobupal Airtal Generi
Slide 11: …in one of Europe's strongest branded markets
…in one of Europe’s strongest branded markets New regulatory environment provides stable outlook Spanish pharma market reacts differently to generic launches compared to other major markets Branded Pharma in Spain Prozac Example – Post Generic Share Erosion Generic penetration has been small US Spai
Slide 12: Ebastine: successful lifecycle management building international brands
Ebastine: successful lifecycle management building international brands Lifecycle Management Fast Growth of Ebastine Franchise During Last 5 Yrs Market Share: Almirall Affiliates (Sp, Fr, Ger, 1990 Ebastine 10mg First Ebastine launch Ita, Port, Bel, Mex) 1995 Micronized Enhanced bioavailability form
Slide 13: Strong R&D track record – focused strategy
Strong R&D track record – focused strategy 7 Proprietary International R&D Products Risk-Reward Balance with High Commercial Potential 2006 Revenue Launch Year Almirall focuses on respiratory and autoimmune diseases: • Balanced level of risk • Ebastine €98 MM 1990 • High commercial potential • Acecl
Slide 14: A pipeline with transformational potential
A pipeline with transformational potential Key Pipeline Products in 2007 Peak Sales Preclinical Ph I Ph II Ph III Registration Expected filing date Potential(1) Aclidinium Bromide (AB) (anti-muscarinic) COPD 2009 (anti-muscarinic AB + Formoterol COPD 2011 €2.0Bn+ +LABA) (anti-muscarinic AB + ICS COP
Slide 15: Aclidinium Bromide: late-stage potential blockbuster
Aclidinium Bromide: late-stage potential blockbuster Addresses the fast expanding COPD market Attractive and • Respiratory market currently valued at $18.6 Bn expanding • COPD is c.30% of total respiratory market COPD Market(1) • In 2006, the Anticholinergic class was the fastest growing respiratory
Slide 16: Aclidinium Bromide: >€2.0 Bn sales potential
Aclidinium Bromide: >€2.0 Bn sales potential Over €2.0 Bn Sales Potential (IMS Forecasts) 70% of Global COPD Market Covered Covered – c.70% • Strong track record in launching 2,500 “fast followers” and late class Exclusivity until 2025 entrants: 2,000 US – 51% – Lexapro: $2.3 Bn Forest Value (€ MM)
Slide 17: Aclidinium Bromide: superior inhalation device
Aclidinium Bromide: superior inhalation device Designed for compliance with global regulatory standards (FDA, EMEA, Japan) • Inhalation device based on technology already approved in the EU • Design modifications agreed with FDA – ongoing interactions • Experienced group of advisors used to ensure a
Slide 18: Summary income statement
Summary income statement CAGR % CAGR % Q1'06- € MM 2004 2005 2006 '04-'06 Q1' 06 Q1' 07 Q1'07 Sales 699.7 736.1 758.0 4.1% 208.5 213.6 2.4% % Change 3.5% 5.2% 3.0% N.A 2.4% Gross Profit 449.2 465.2 474.7 2.8% 132.5 138.9 4.8% % Margin 64.2% 63.2% 62.6% 63.6% 65.0% Other Income 45.5 62.3 96.1 45.4% 1
Slide 19: Sales breakdown by geography
Sales breakdown by geography (€MM) CAGR 04-06 800 736 758 700 76 79 56 +23.5% +15.4% 47 45 39 Affiliates: +19.4% 600 24 32 51 50 - 1.9% 61 - 0.8% 66 Spain: - 1.3% 400 531 521 517 200 0 2004 2005 2006 Spain France Italy Rest of Affiliates(1) RoW(2) Notes 1. Includes Mexico, Belgium, Germany and Portu
Slide 20: Sales breakdown by top 10 products
Sales breakdown by top 10 products € MM IFRS Var % % of % of % of API 2004 2005 2006 '04-'05 '05-'06 Sales Sales Sales Ebastine 70.6 10% 98.6 13% 98.3 13% 39.6% (0.3)% Atorvastatin 74.4 11% 78.3 11% 83.7 11% 5.3% 6.9% Aceclofenac 57.2 8% 61.9 8% 60.9 8% 8.3% (1.7)% Salmet + Flut 53.1 8% 54.5 7% 56.4
Slide 21: Strong cash flow generation and balance sheet
Strong cash flow generation and balance sheet €54 MM Net Cash in Q1 2007 Strong Cash Flow Generation A Strong Balance Sheet € MM 2004 2005 2006 € MM 2004 2005 2006 Q1 2007 Profit Before Tax 102.8 137.9 145.8 Goodwill 40.0 40.0 47.3 47.1 % Margin 14.7% 18.7% 19.2% Intangible assets 51.6 73.7 85.2 82.
Slide 22: Use of proceeds and dividend policy
Use of proceeds and dividend policy Use of Proceeds • Primary proceeds for use in corporate development projects – M&A / in-licensing projects in advanced stages of development – M&A / in-licensing agreements in earlier stages of development • Potential acquisition of a medium-sized/specialised Euro
Slide 23: Conclusion
Conclusion Strategic Goals Maintain Leadership in Expand international presence Leverage R&D Pipeline Enhance Margin and Cash Spain Flow Significant Achievements to Date Confidence in Future Upside • Leading Spanish pharmaceutical company • Successful pipeline development, led by Aclidinium Bromide
Slide 24: Almirall
i] . (% Almirall Solutions thinking of you